Is AMLX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The LUCIDITY Phase 3 readout, with product revenue at None (Relyvrio withdrawn in 2024). The bear case rests on the concentration risk is the dominant one: a single Phase 3 readout in a small 78-patient trial decides most of the equity value, and small trials are more vulnerable to placebo response and endpoint variability than large ones. Analysts covering it are spread from $21.00 to $40.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The concentration risk is the dominant one: a single Phase 3 readout in a small 78-patient trial decides most of the equity value, and small trials are more vulnerable to placebo response and endpoint variability than large ones. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $21.00, -8.0% from the $22.82 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The LUCIDITY Phase 3 readout. Topline data from the 78-participant pivotal trial of avexitide in post-bariatric hypoglycemia are expected in late August or early September 2026. The most optimistic analyst target on AMLX is $40.00, +75.3% from the $22.82 price. That figure is only reachable if this thesis works close to its best case.

The concentration risk is the dominant one: a single Phase 3 readout in a small 78-patient trial decides most of the equity value, and small trials are more vulnerable to placebo response and endpoint variability than large ones. Amylyx has already failed a confirmatory Phase 3 once, with Relyvrio withdrawn from the market in 2024, so execution credibility is not assumed by the market. Even a positive dataset leaves FDA review risk, label risk, and the operational cost of building a commercial organization for a rare condition. The company generates no product revenue and burns roughly $40 million a quarter, so any delay pushes it toward a financing that would dilute existing holders. There is also a legacy legal item: a securities class action tied to 2022 to 2023 Relyvrio launch statements was settled for $6.5 million, with preliminary court approval in May 2026 and a final approval hearing scheduled for September 2026. The most pessimistic published target is $21.00, -8.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Clinical-stage biotech whose lead asset avexitide targets post-bariatric hypoglycemia, with a Phase 3 readout as the near-term swing factor.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The LUCIDITY Phase 3 readout) stalling in the reported numbers rather than in the narrative, the risk above (the concentration risk is the dominant one: a single Phase 3 readout in a small 78-patient trial decides most of the equity value, and small trials are more vulnerable to placebo response and endpoint variability than large ones) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Amylyx is a clinical-stage biotech developing drugs for conditions with few approved options. Its lead candidate, avexitide, is in Phase 3 for post-bariatric hypoglycemia, and it also runs programs in Wolfram syndrome (AMX0035), ALS (AMX0114) and a preclinical asset (AMX0318). It sells no products today.

Not meaningfully. Its only approved product, Relyvrio for ALS, was withdrawn from the market in 2024 after the confirmatory PHOENIX Phase 3 trial failed to show benefit. Since then Amylyx has operated as a pre-revenue clinical-stage company funded entirely by its balance sheet.

Avexitide is a GLP-1 receptor antagonist for post-bariatric hypoglycemia, a condition where gastric bypass patients suffer severe blood-sugar crashes. There is no FDA-approved treatment for it. Because avexitide is the only Phase 3 asset in the portfolio, its pivotal LUCIDITY result carries most of the company's near-term value.